SciBase Shows Strong Commitment in Ongoing Rights Issue Amidst Shareholder Support

Increased Commitment in SciBase Rights Issue

On January 22, 2026, SciBase Holding AB, a prominent developer of AI-driven diagnostic solutions aimed at addressing skin disorders, announced increased participation from major shareholders in its ongoing rights issue. This strategic move underscores SciBase's commitment to strengthening its financial foundation and advancing its innovative technologies in dermatology.

The rights issue aims to raise approximately 83 million SEK, with subscriptions scheduled to conclude on January 26, 2026. As of now, several existing shareholders have pledged to subscribe for roughly 39.4 million SEK. This figure represents about 47.6% of the total rights issue. Recently, it has been confirmed that Life Science Investment Fund 1, one of SciBase's larger stakeholders, has subscribed to its pro rata allocation, which accounts for around 5% of the rights issue.

Jan Poulsen, CEO of Life Science Investment Fund 1, expressed enthusiasm for the decision, stating, "After evaluating SciBase's production capabilities during our recent visit to their facility in Uppsala, and considering our updated research on SciBase’s outlook for 2026, we are excited to fulfill our subscription. This will also enhance our stake in SciBase through the conversion of our TO2 options."

Additionally, SciBase’s second largest shareholder, Castle Biosciences, has committed to invest 23 million SEK in the rights issue alongside their proportional share of 11.6%. When combined with contributions from other shareholders, this brings the total commitments to approximately 82.7% of the rights issue.

Moreover, members of SciBase’s management have also shown their confidence in the company’s future by subscribing for shares totaling 0.6 million SEK beyond their respective pro-rata commitments. These developments not only demonstrate strong insider support but also highlight the confidence that shareholders have in the ongoing efforts of SciBase to redefine diagnostics in the field of dermatology.

SciBase is renowned for its proprietary platform, Nevisense, which integrates artificial intelligence with advanced electrical impedance spectroscopy (EIS) technology to enhance the accuracy of skin disorder diagnostics. This innovative approach plays a crucial role in the early detection and prevention of skin conditions, ultimately aiming to reduce patient suffering and healthcare costs. With over two decades of research backing their technologies from the prestigious Karolinska Institute in Stockholm, SciBase is at the forefront of dermatological innovation.

The company has been publicly listed on the Nasdaq First North Growth Market since June 2, 2015, providing opportunities for further growth and expansion through its ongoing commitments to research and shareholder engagement.

For more updates and detailed information, stakeholders can visit the official SciBase website or check their investor relations for the latest press releases and financial reports. As SciBase navigates through this rights issue, the company's commitment to advancing skin health management continues to drive its mission forward.

For further inquiries, Pia Renaudin, CEO of SciBase, can be contacted at +46732069802 or via email at [email protected] Additionally, the Certified Advisor for the company is DNB Carnegie Investment Bank AB, reachable at +46 8 588 68 570 or [email protected].